GSK/Ionis’s hepatitis B drug bepirovirsen granted global-first approval recommendation in Japan, which has also reimbursed its second iPSC therapy.
GSK/Ionis’s hepatitis B drug bepirovirsen granted global-first approval recommendation in Japan, which has also reimbursed its second iPSC therapy.